27 research outputs found

    Drive (Quantum) Safe! – Towards PQ Authentication for V2V Communications

    Get PDF
    We tackle a challenging problem at the intersection of two emerging technologies: post-quantum cryptography (PQC) and vehicle-to-vehicle (V2V) communication with its strict requirements. We are the first to devise and evaluate a practical, provably secure design for integrating PQ authentication into the IEEE 1609.2 V2V security ecosystem. By theoretically and empirically analyzing the three PQ signature algorithms selected for standardization by NIST, as well as XMSS (RFC 8391), we propose a Partially Hybrid design—a tailored fusion of classical cryptography and PQC—for use during the nascent transition period to PQC. As opposed to a direct substitution of PQC for classical cryptography, our design meets the unique constraints of standardized V2V protocols

    Adaptive Frequency Hopping Algorithms for Multicast Rendezvous in DSA Networks

    Get PDF
    Abstract-Establishing communications in a dynamic spectrum access (DSA) network requires communicating nodes to "rendezvous" before transmitting their data packets. Frequency hopping (FH) provides an effective method for rendezvousing without relying on a predetermined control channel. FH rendezvous protocols have mainly targeted pairwise rendezvous, using fixed (non-adaptive) FH sequences and assuming a homogeneous spectrum environment, i.e., all nodes perceive the same spectrum opportunities. In this paper, we address these limitations by developing three multicast rendezvous algorithms: AMQFH, CMQFH, and nested-CMQFH. The three algorithms are intended for asynchronous spectrum-heterogeneous DSA networks. They provide different tradeoffs between speed and robustness to node compromise. We use the uniform k-arbiter and the Chinese remainder theorem (CRT) quorum systems to design our multicast rendezvous algorithms. We also design two "optimal" channel ordering mechanisms for channel sensing and assignment, one for AMQFH and the other for CMQFH and nested-CMQFH. Finally, we develop a proactive out-of-band sensing based dynamic FH (DFH) algorithm for online adaptation of the FH sequences used in the proposed rendezvous algorithms. Extensive simulations are used to evaluate our algorithms

    Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

    Get PDF
    Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

    Full Frame Encryption and Modulation Obfuscation Using Channel-Independent Preamble Identifier

    Full text link

    Secrecy beyond encryption: obfuscating transmission signatures in wireless communications

    Full text link

    Towards Protecting 5G Sidelink Scheduling in C-V2X Against Intelligent DoS Attacks

    Full text link

    Exploiting Frame Preamble Waveforms to Support New Physical-Layer Functions in OFDM-Based 802.11 Systems

    No full text
    corecore